|Target disease||Glaucoma / Ocular hypertension|
|Development stage||Phase II trial in Japan|
|License out to||Wakamoto Company, Ltd.|
|Overview||The drug has been confirmed by animal tests, etc. to have strong ocular hypotensive effect and neuroprotective action, and is considered to have a new mode of action.
It is a development product optimized based on a seed compound of our compound library. Through the Drug Western method, the target protein has been identified as a heat shock protein Hsp90. We made a presentation of the target protein at ARVO (*) held in May 2013. A glaucoma drug binding to Hsp90 will be the first in the world.
In July 2018 phase II clinical study was completed with the good results. Currently, Wakamoto has been advancing preparations towards the domestic phase III clinical study.
*ARVO: The Association for Research in Vision and Ophthalmology 2012
One of the largest international congresses in the area of ophthalmology
|2013||Mar.||Licensed rights in Japan to Wakamoto Co., Ltd.|
|Dec.||Initiated non-clinical studies|
|2016||Mar.||Completed non-clinical studies|
|Mar.||Initiated phase I trial in Japan|
|2017||Mar.||Completed phase I trial in Japan|
|Aug.||Initiated phase II trial in Japan|
|2018||Jul.||Completed phase II trial in Japan|